Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: mike head who wrote (339)	12/31/1998 10:41:00 PM
From: Larry Liebman	Read Replies (3) \| Respond to of 1073

Richard, this is the first time since the early '97 where I've seen biotechs being actively accumulated. More to the point, I just received the annual "Janus Report"(and these guys have been incredibly good this year). They're starting a new fund to be known as "Global Life Sciences", to be managed by Tom Malley(?). The Janus report states: "The whole life sciences group is entering a new era. And while it might be another 5 to 10 years before some of these companies reach their full potential, he's convinced that when they do, the industry as a whole will have even a greater impact on economic growth....For now he(Malley) believes that biotechnology and pharmaceutical companies are the ones to watch". In looking through other Janus funds, I noted they've purchased Incyte, Medimmune, and Sepracor. I believe I hear the ice thawing for 2nd and 3rd tier biotechs. BTW, I had an extremely interesting talk with the ARIA CFO today. Had I not a slug of stock/warrants I would have bought more at $1 1/2. Here's to the renaissance of biotechs in '99!!!!